SE458237B - Foerfarande och medel foer bestaemmning av immunkomplex eller aggregerade gammaglobuliner - Google Patents

Foerfarande och medel foer bestaemmning av immunkomplex eller aggregerade gammaglobuliner

Info

Publication number: SE458237B
Authority: SE; Sweden
Prior art keywords: immune complexes; layer; sample; polyethylene glycol; washed
Prior art date: 1983-10-03

Application number

SE8306605A

Other languages

English (en)

Swedish (sv)

Other versions

SE8306605D0 (sv

SE8306605L (sv

Inventor

A N Ozkan

Original Assignee

Biostar Med Prod

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-10-03

Filing date

1983-11-30

Publication date

1989-03-06

1983-11-30 Application filed by Biostar Med Prod filed Critical Biostar Med Prod

1983-11-30 Publication of SE8306605D0 publication Critical patent/SE8306605D0/xx

1985-04-04 Publication of SE8306605L publication Critical patent/SE8306605L/xx

1989-03-06 Publication of SE458237B publication Critical patent/SE458237B/sv

Links

210000002966 serum Anatomy 0.000 title claims description 41
238000004458 analytical method Methods 0.000 title description 7
229920001223 polyethylene glycol Polymers 0.000 claims abstract description 62
102000004190 Enzymes Human genes 0.000 claims abstract description 30
108090000790 Enzymes Proteins 0.000 claims abstract description 30
239000002202 Polyethylene glycol Substances 0.000 claims abstract description 22
230000008859 change Effects 0.000 claims abstract description 17
239000010410 layer Substances 0.000 claims description 42
239000000758 substrate Substances 0.000 claims description 35
239000007787 solid Substances 0.000 claims description 33
108010074605 gamma-Globulins Proteins 0.000 claims description 21
238000000034 method Methods 0.000 claims description 21
239000000427 antigen Substances 0.000 claims description 19
102000036639 antigens Human genes 0.000 claims description 19
108091007433 antigens Proteins 0.000 claims description 19
239000007788 liquid Substances 0.000 claims description 14
229920003023 plastic Polymers 0.000 claims description 12
239000004033 plastic Substances 0.000 claims description 12
239000007853 buffer solution Substances 0.000 claims description 11
239000003795 chemical substances by application Substances 0.000 claims description 11
238000003018 immunoassay Methods 0.000 claims description 10
239000000203 mixture Substances 0.000 claims description 10
108060003951 Immunoglobulin Proteins 0.000 claims description 9
238000003556 assay Methods 0.000 claims description 9
102000018358 immunoglobulin Human genes 0.000 claims description 9
230000000890 antigenic effect Effects 0.000 claims description 6
230000008569 process Effects 0.000 claims description 6
238000001179 sorption measurement Methods 0.000 claims description 6
230000015572 biosynthetic process Effects 0.000 claims description 5
239000011247 coating layer Substances 0.000 claims description 4
230000005855 radiation Effects 0.000 claims 2
239000000654 additive Substances 0.000 claims 1
230000000996 additive effect Effects 0.000 claims 1
239000003550 marker Substances 0.000 claims 1
239000000941 radioactive substance Substances 0.000 claims 1
229920000642 polymer Polymers 0.000 abstract description 25
238000005406 washing Methods 0.000 abstract description 17
229920000915 polyvinyl chloride Polymers 0.000 abstract description 5
239000004800 polyvinyl chloride Substances 0.000 abstract description 5
239000000872 buffer Substances 0.000 abstract description 4
229920002307 Dextran Polymers 0.000 abstract description 2
229920005862 polyol Polymers 0.000 abstract 1
150000003077 polyols Chemical class 0.000 abstract 1
238000012360 testing method Methods 0.000 description 58
239000000243 solution Substances 0.000 description 40
239000000523 sample Substances 0.000 description 39
229940027941 immunoglobulin g Drugs 0.000 description 19
238000006243 chemical reaction Methods 0.000 description 14
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
239000000463 material Substances 0.000 description 13
238000010790 dilution Methods 0.000 description 12
239000012895 dilution Substances 0.000 description 12
201000010099 disease Diseases 0.000 description 12
102000004169 proteins and genes Human genes 0.000 description 9
108090000623 proteins and genes Proteins 0.000 description 9
229920001213 Polysorbate 20 Polymers 0.000 description 8
210000001124 body fluid Anatomy 0.000 description 8
239000010839 body fluid Substances 0.000 description 8
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 8
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 8
239000012857 radioactive material Substances 0.000 description 8
206010039073 rheumatoid arthritis Diseases 0.000 description 8
239000008055 phosphate buffer solution Substances 0.000 description 7
238000012286 ELISA Assay Methods 0.000 description 6
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 6
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 6
201000000596 systemic lupus erythematosus Diseases 0.000 description 6
XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 5
229910019142 PO4 Inorganic materials 0.000 description 5
210000004027 cell Anatomy 0.000 description 5
239000003599 detergent Substances 0.000 description 5
208000006454 hepatitis Diseases 0.000 description 5
231100000283 hepatitis Toxicity 0.000 description 5
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
239000010452 phosphate Substances 0.000 description 5
238000003127 radioimmunoassay Methods 0.000 description 5
241000700605 Viruses Species 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
239000011248 coating agent Substances 0.000 description 4
238000000576 coating method Methods 0.000 description 4
239000000975 dye Substances 0.000 description 4
238000011534 incubation Methods 0.000 description 4
239000013642 negative control Substances 0.000 description 4
229920000620 organic polymer Polymers 0.000 description 4
239000013641 positive control Substances 0.000 description 4
239000000843 powder Substances 0.000 description 4
241000894006 Bacteria Species 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
239000004793 Polystyrene Substances 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
238000002835 absorbance Methods 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
102000005936 beta-Galactosidase Human genes 0.000 description 3
108010005774 beta-Galactosidase Proteins 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
238000001704 evaporation Methods 0.000 description 3
229940127121 immunoconjugate Drugs 0.000 description 3
229920002223 polystyrene Polymers 0.000 description 3
238000004393 prognosis Methods 0.000 description 3
208000030507 AIDS Diseases 0.000 description 2
102000008186 Collagen Human genes 0.000 description 2
108010035532 Collagen Proteins 0.000 description 2
102000016942 Elastin Human genes 0.000 description 2
108010014258 Elastin Proteins 0.000 description 2
206010062016 Immunosuppression Diseases 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
239000008118 PEG 6000 Substances 0.000 description 2
102000003992 Peroxidases Human genes 0.000 description 2
229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
239000011545 carbonate/bicarbonate buffer Substances 0.000 description 2
210000001175 cerebrospinal fluid Anatomy 0.000 description 2
229920001436 collagen Polymers 0.000 description 2
239000013068 control sample Substances 0.000 description 2
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
229920002549 elastin Polymers 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
230000001506 immunosuppresive effect Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
108040007629 peroxidase activity proteins Proteins 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
210000002381 plasma Anatomy 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
239000012089 stop solution Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
238000009736 wetting Methods 0.000 description 2
GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
ORLFVWPPBMVPNZ-UHFFFAOYSA-N 1-(6-methylheptyl)-4-[4-(6-methylheptyl)phenoxy]benzene Chemical compound C1=CC(CCCCCC(C)C)=CC=C1OC1=CC=C(CCCCCC(C)C)C=C1 ORLFVWPPBMVPNZ-UHFFFAOYSA-N 0.000 description 1
HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
229930105110 Cyclosporin A Natural products 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
102000006354 HLA-DR Antigens Human genes 0.000 description 1
108010058597 HLA-DR Antigens Proteins 0.000 description 1
102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
230000009471 action Effects 0.000 description 1
KBTZIRDXUNOZMF-UHFFFAOYSA-N benzene-1,2-diamine;phosphoric acid Chemical compound OP(O)(O)=O.NC1=CC=CC=C1N KBTZIRDXUNOZMF-UHFFFAOYSA-N 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000001934 delay Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000010586 diagram Methods 0.000 description 1
MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
150000008195 galaktosides Chemical class 0.000 description 1
229940098197 human immunoglobulin g Drugs 0.000 description 1
230000036039 immunity Effects 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
230000002621 immunoprecipitating effect Effects 0.000 description 1
239000003547 immunosorbent Substances 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
229940124589 immunosuppressive drug Drugs 0.000 description 1
230000006872 improvement Effects 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
XMBWDFGMSWQBCA-YPZZEJLDSA-N iodane Chemical compound [125IH] XMBWDFGMSWQBCA-YPZZEJLDSA-N 0.000 description 1
229940044173 iodine-125 Drugs 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
239000011344 liquid material Substances 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
AJDUTMFFZHIJEM-UHFFFAOYSA-N n-(9,10-dioxoanthracen-1-yl)-4-[4-[[4-[4-[(9,10-dioxoanthracen-1-yl)carbamoyl]phenyl]phenyl]diazenyl]phenyl]benzamide Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C=CC=C2NC(=O)C(C=C1)=CC=C1C(C=C1)=CC=C1N=NC(C=C1)=CC=C1C(C=C1)=CC=C1C(=O)NC1=CC=CC2=C1C(=O)C1=CC=CC=C1C2=O AJDUTMFFZHIJEM-UHFFFAOYSA-N 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
239000011241 protective layer Substances 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
239000000376 reactant Substances 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
210000000582 semen Anatomy 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000012289 standard assay Methods 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
210000001138 tear Anatomy 0.000 description 1
239000012085 test solution Substances 0.000 description 1
238000004448 titration Methods 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000001043 yellow dye Substances 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
- G01N33/545—Synthetic resin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Chemical & Material Sciences (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Cell Biology (AREA)
Pathology (AREA)
Biotechnology (AREA)
General Physics & Mathematics (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Rheumatology (AREA)
Rehabilitation Therapy (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Investigating Or Analysing Biological Materials (AREA)
Automatic Analysis And Handling Materials Therefor (AREA)

SE8306605A 1983-10-03 1983-11-30 Foerfarande och medel foer bestaemmning av immunkomplex eller aggregerade gammaglobuliner SE458237B (sv)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US53816983A	1983-10-03	1983-10-03

Publications (3)

Publication Number	Publication Date
SE8306605D0 SE8306605D0 (sv)	1983-11-30
SE8306605L SE8306605L (sv)	1985-04-04
SE458237B true SE458237B (sv)	1989-03-06

Family

ID=24145804

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE8306605A SE458237B (sv)	1983-10-03	1983-11-30	Foerfarande och medel foer bestaemmning av immunkomplex eller aggregerade gammaglobuliner

Country Status (4)

Country	Link
DK (1)	DK47484A (da)
GR (1)	GR80292B (da)
JO (1)	JO1386B1 (da)
SE (1)	SE458237B (da)

1983
- 1983-11-30 SE SE8306605A patent/SE458237B/sv not_active IP Right Cessation
1984
- 1984-02-02 DK DK47484A patent/DK47484A/da not_active Application Discontinuation
- 1984-09-05 GR GR80292A patent/GR80292B/el unknown
- 1984-10-02 JO JO19841386A patent/JO1386B1/en active

Also Published As

Publication number	Publication date
SE8306605D0 (sv)	1983-11-30
DK47484A (da)	1985-04-04
SE8306605L (sv)	1985-04-04
GR80292B (en)	1985-01-31
JO1386B1 (en)	1986-11-30
DK47484D0 (da)	1984-02-02

Legal Events

Date

Code

Title

Description

1995-01-31

NUG

Patent has lapsed

Ref document number: 8306605-0

Effective date: 19910704

Format of ref document f/p: F

Publication	Publication Date	Title
CA1225586A (en)	1987-08-18	Method of performing an immuno-assay, article for use therein and method for making such article
US4294817A (en)	1981-10-13	Method of fluoro immunoassay
US4681782A (en)	1987-07-21	Article for determining the presence of immune complexes
US4290997A (en)	1981-09-22	Apparatus for automatic measurement of the results of agglutination tests
FI76888B (fi)	1988-08-31	Nya medel och foerpackningar foer immunologiska analyser.
JP3330604B2 (ja)	2002-09-30	固相免疫学的検定法
US4757002A (en)	1988-07-12	Method and kit for the estimation of serum immunoglobulin
JPH07508102A (ja)	1995-09-07	アッセイ
EP0019277A1 (en)	1980-11-26	A process for detecting the presence of an antigen in a specimen
EP0173295A1 (en)	1986-03-05	Assay for simultaneous detection of antigen and antibody in given serum
US4774177A (en)	1988-09-27	Immunoassay method for detection of antibodies and antigens
EP0350233B1 (en)	1994-10-05	An article for performing immunological assays utilizing organic dyes and methods for producing and utilizing same
JPH01121755A (ja)	1989-05-15	免疫検定キット及び免疫検定方法
US5213963A (en)	1993-05-25	Procedure for finding and identifying red cell antibodies by means of the solid phase method
JPH02157656A (ja)	1990-06-18	固相法により赤血球抗体を探索し、同定する方法
SE458237B (sv)	1989-03-06	Foerfarande och medel foer bestaemmning av immunkomplex eller aggregerade gammaglobuliner
JP2549305B2 (ja)	1996-10-30	独立多重式免疫測定法診断システム
SE460564B (sv)	1989-10-23	Testsats och foerfarande foer immunanalys med prefabricerade komplex av maerkt antikropp och analytspecifik antikropp
Ohgama et al.	1996	A new solid‐phase assay system using magnetic force on blood group serology
Pande	2023	Immunochemistry Techniques
SU1720010A1 (ru)	1992-03-15	Способ определени изотипа антител
WO2017130829A1 (ja)	2017-08-03	マイクロアレイ、マイクロアレイの製造方法、検査方法、及び検査キット
Million et al.	1998	A stable reagent system for screening and identifying red blood cell irregular antibodies: application to commercial antibodies
SU899043A1 (ru)	1982-01-23	Способ вы влени менингококкового антигена
JPS63503241A (ja)	1988-11-24	特にｈｔｌｖ３ウイルスによってひき起こされた感染の実験室的改良診断方法